Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US
暂无分享,去创建一个
Milton C Weinstein | Taige Hou | A David Paltiel | Robert A Parker | Bruce R Schackman | Rochelle P Walensky | M. Hughes | M. Weinstein | R. Walensky | R. Parker | K. Freedberg | P. Sax | B. Schackman | A. Paltiel | T. Hou | Kenneth A Freedberg | Paul E Sax | Michael D Hughes | Pamela P Pei | X Cynthia Li | Melanie R Gaynes | P. Pei | Melanie R. Gaynes | X. C. Li | Taige Hou | R. Parker
[1] U. Siebert,et al. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence. , 2013, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.
[2] S. Sansom,et al. Cost Effectiveness of the National HIV/AIDS Strategy Goal of Increasing Linkage to Care for HIV-Infected Persons , 2012, Journal of acquired immune deficiency syndromes.
[3] M. Weinstein,et al. Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States , 2013, Annals of Internal Medicine.
[4] Sandeep Vijan,et al. The value of medical spending in the United States, 1960-2000. , 2006, The New England journal of medicine.
[5] D. Katzenstein,et al. Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 , 2011, Annals of Internal Medicine.
[6] Lynne Peeples,et al. Class-sparing regimens for initial treatment of HIV-1 infection. , 2008, The New England journal of medicine.
[7] John B. Wong,et al. Heterogeneity and uncertainty , 2014 .
[8] Michael Rayment,et al. Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.
[9] W. Gerth,et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[10] Adriano Lazzarin,et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial , 2009, The Lancet.
[11] Clare Brennan,et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study , 2013, The Lancet.
[12] J. Manson,et al. Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial , 2014, Annals of Internal Medicine.
[13] A. Lazzarin,et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. , 2005, AIDS.
[14] Bas Groot Koerkamp,et al. Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods. , 2006, Health economics.
[15] Milton C Weinstein,et al. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. , 2006, The New England journal of medicine.
[16] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[17] Michael E. Chernew,et al. Willingness to Pay for a Quality-adjusted Life Year , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.
[18] A. Lazzarin,et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial , 2011, The Lancet.
[19] S. Grosse. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold , 2008, Expert review of pharmacoeconomics & outcomes research.
[20] M. Weinstein,et al. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] B. Clotet,et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study , 2014, The Lancet.
[22] Joel E Gallant,et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.
[23] S. Walmsley,et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. , 2013, The New England journal of medicine.
[24] M. Johnson,et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures , 2006, AIDS.
[25] R. Kuchenbecker,et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. , 2011, Annals of internal medicine.
[26] D. Aschenbrenner. New Drug to Treat HIV Infection , 2011 .
[27] M G Myriam Hunink,et al. Uncertainty and Patient Heterogeneity in Medical Decision Models , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.
[28] M. Roberts,et al. What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? , 2008, Medical care.
[29] A. Willan,et al. Value of Information and Pricing New Healthcare Interventions , 2012, PharmacoEconomics.
[30] Milton C Weinstein,et al. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. , 2005, The New England journal of medicine.
[31] Richard D Moore,et al. Late presentation for human immunodeficiency virus care in the United States and Canada. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] J. Lave,et al. Willingness to Pay for a Quality-Adjusted Life Year: Implications for Societal Health Care Resource Allocation , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.
[33] S. Hammer,et al. HIV Vaccine Research: The Way Forward , 2008, Science.
[34] D. Whynes,et al. Eliciting Willingness to Pay: Comparing Closed-Ended with Open-Ended and Payment Scale Formats , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.
[35] J. Nachega,et al. Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] Joshua T. Cohen,et al. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.
[37] M. Johnson,et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures , 2005, AIDS.
[38] K. White,et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks , 2012, The Lancet.
[39] Lynne Peeples,et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. , 2009, The New England journal of medicine.
[40] Kenneth A. Freedberg,et al. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial , 2012, AIDS.
[41] M. Sculpher,et al. Decision Modelling for Health Economic Evaluation , 2006 .
[42] Mardge H. Cohen,et al. HIV and Aging: State of Knowledge and Areas of Critical Need for Research. A Report to the NIH Office of AIDS Research by the HIV and Aging Working Group , 2012, Journal of acquired immune deficiency syndromes.
[43] V. Retèl,et al. A Systematic and Critical Review of the Evolving Methods and Applications of Value of Information in Academia and Practice , 2012, PharmacoEconomics.